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Abstract
Background: Benzophenone-3 (BZ-3) is a common ultraviolet (UV) absorbing compound in sunscreens. It is the 
most bioavailable species of all UV-absorbing compounds after topical application and can be found in plasma and 
urine.
Objectives: The aim of this study was to develop a reverse-phase high performance liquid chromatography (HPLC) method 
for determining the amounts BZ-3 and its metabolite 2,4-dihydroxybenzophenone (DHB) in human urine. The method had to 
be suitable for handling a large number of samples. It also had to be rapid and simple, but still sensitive, accurate and reproduc-
ible. The assay was applied to study the urinary excretion pattern after repeated whole-body applications of a commercial 
sunscreen, containing 4% BZ-3, to 25 healthy volunteers.
Methods: Each sample was analyzed with regard to both conjugated/non-conjugated BZ-3 and conjugated/non-conjugated 
DHB, since both BZ-3 and DHB are extensively conjugated in the body. Solid-phase extraction (SPE) with C8 columns 
was followed by reverse-phase HPLC. For separation a Genesis C18 column was used with an acethonitrile-water mobile 
phase and the UV-detector was set at 287 nm.
Results: The assay was linear r
2   0.99, with detection limits for BZ-3 and DHB of 0.01 μmol L
−1 and 0.16 μmol L
−1 
respectively. Relative standard deviation (RSD) was less than 10% for BZ-3 and less than 13% for DHB.The excretion 
pattern varied among the human volunteers; we discerned different patterns among the individuals.
Conclusions: The reverse-phase HPLC assay and extraction procedures developed are suitable for use when a large num-
ber of samples need to be analyzed and the method fulﬁ  lled our objectives. The differences in excretion pattern may be due 
to differences in enzyme activity but further studies, especially about genetic polymorphism, need to be performed to verify 
this ﬁ  nding.
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Introduction
Ultraviolet (UV) radiation from the sun has adverse effects on human skin; it causes photoaging, sunburn 
and most seriously, skin cancer. The protective ozone layer has been subject to destruction and the areas 
where the ozone layer is thin have higher incidence of skin cancer.
Malignant melanoma is one of the most rapidly increasing types of cancer in Sweden and non-mela-
noma skin cancer is also increasing. UV-radiation from the sun is the most important etiological factor.
Sunscreens are widely used to protect us against harmful radiation. Benzophenone-3 (BZ-3) has 
been a commonly used ﬁ  lter in sunscreens for the last few decades; it has both UVA and UVB pro-
tecting properties. It is an organic chemical absorber with a molecule weight (MW) of 228.25 and 
CAS number 131-57-7. The structure is shown in Figure 1a (ChemIDplus). The ultimate sunscreen 
stays on the skin and its protective mechanism functions there. However, BZ-3 is relatively lipophilic 2
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(log P 3.64 ± 0.37) and several reports have shown 
that BZ-3 penetrates the skin and is excreted in 
urine (Hayden, Roberts et al. 1997; Gustavsson 
Gonzalez, Farbrot et al. 2002; Janjua, Mogensen 
et al. 2004; Sarveiya, Risk et al. 2004; Gonzalez, 
Farbrot et al. 2006). Urine is the major excretion 
pathway and 2,4-dihydroxybenzophenone (DHB), 
one of the major metabolites in rats (Okereke, 
Kadry et al. 1993). DHB has a MW of 214.22 and 
CAS number 131-56-6. The structure is shown in 
Figure 1b. BZ-3 is the most bioavailable com-
pound of all UV-absorbing chemicals, (Nash, 
2006) and is extensively conjugated in the human 
body.
We wanted to develop an assay to measure the 
amounts of BZ-3 and DHB in human urine. The 
method had to suit our needs. For example, it had 
to be possible to handle a large number of samples 
easily; hence it had to be rapid and simple but still 
sensitive, accurate and reproducible. Several meth-
ods using high performance liquid chromatography 
(HPLC) and BZ-3 have been described (Abdel-
Nabi, Kadry et al. 1992; Jiang, Hayden et al. 1996; 
Vanquerp, Rodriguez et al. 1999; Chisvert, 
Pascual-Marti et al. 2001) and this work has been 
developed to some extent on the basis of previously 
described method (Abdel-Nabi, Kadry et al. 1992). 
However, there are few methods for extraction of 
BZ-3 and DHB in human urine after it has been 
metabolized by the human body (Sarveiya, Risk 
et al. 2004). Abdel-Nabi et al. used urine from rats 
(Abdel-Nabi, Kadry et al. 1992). Several other 
methods are designed for product evaluation and 
not for extraction from biological media. None of 
the methods ﬁ  tted our needs completely and for 
that reason we developed this method. More than 
1000 urine samples were collected and each was 
analyzed for conjugated/non-conjugated BZ-3 and 
conjugated/non-conjugated DHB. More than 4000 
analyses were performed.
The method we developed was used to study the 
excretion pattern of BZ-3 and DHB in urine after 
repeated topical whole-body applications of a sun-
screen containing BZ-3 to 25 human volunteers.
Experimental
Reagents
BZ-3 (2-hydroxy-4-methoxybenzophenone), DHB 
(2,4-dihydroxybenzophenone) and benzophenone 
(BZ), all purity 99%, (Aldrich Chem).
Methanol (HPLC-grade), acethonitrile (HPLC-
grade) and triﬂ  uoroacetic acid (TFA) (Merck).
β-glucurunidase/arylsulfatase obtained from 
Helix pomata (Boehringer Mannheim).
Chromatography
A gradient HPLC-system with a pump PU-1580 
(Jasco), a 50 μl loop injector and a SPD-10A VP 
uv-vis detector (Schimadzu) were used. Chromato-
graphic separation was achieved on a Genesis C18 
ID (4.6 mm × 150 mm) column. A Genesis C18 
(20 mm × 4.0 mm) was used as the precolumn.
The mobile phase was acethonitrile:dionized 
ultra ﬁ  ltered water (UF) (0.45 μm) 44:66 (v/v) with 
1 mL TFA to 10000 mL mobile phase with gradient 
elution according to Table 1. UV absorption was 
done at 287 nm. The runtime was 31.5 min.
Standard solutions
One stock solution containing 4.0 mmol L
−1 BZ-3 
and one stock solution containing 3.0 mmol L
−1 
DHB in 70:30 (v/v) methanol: UF water were used. 
Working standard solutions were prepared in 
methanol at ﬁ  ve concentrations, 0.04 mmol L
−1 
BZ-3, 0.03 mmol L
−1 DHB, 0.4 mmol L
−1 BZ-3, 
0.3 mmol L
−1 DHB, 4 mmol L
−1 BZ-3, 3 mmol 
L
−1 DHB, 40 mmol L
−1 BZ-3, 30 mmol L
−1 DHB 
and 100 mmol L
−1 BZ-3, 75 mmol L
−1 DHB. All 
solutions were prepared in volumetric ﬂ  asks, class 
A and kept refrigerated at temperature between 2 
and 8 °C. Fresh standards were prepared every 
month.
Figure 1. Chemical structure of BZ-3 (a) and DHB (b).
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Sample pre-treatment
Pre-treatment before extracting
conjugated samples
The urine samples were centrifuged at 2100 g for 
10 minutes. 1 mL urine was used. 100 μL gluc-
uronidase/arylsulphatase and 25 μL internal standard 
were added. The sample was incubated at 37 °C 16 
hours. The sample was diluted with 2 mL phosphate 
buffer (50 mmol L
−1, pH 6.5). Most samples were 
diluted 1:20 with 0.9% NaCl-solution.
Pre-treatment for non-conjugated samples
The urine samples were centrifuged at 2100 g for 
10 minutes. 1 mL was used. 25 μL internal standard 
was added. The sample was diluted with 2 mL 
phosphate buffer.
Solid-phase extraction
Extraction was performed with a vacuum manifold 
and solid-phase extraction (SPE) columns C8, 100 mg, 
6 mL (Isolute Inc., purchased from Sorbent AB).
1.  The column was activated with 2 mL methanol. 
The vacuum was turned off when the methanol 
reached the top of the sorbent, to prevent the 
column from drying. The procedure was 
repeated once.
2. The column was rinsed with 2 mL phosphate 
buffer. The vacuum was turned off when the 
buffer reached the top of the sorbent bed, to 
prevent column from drying. The procedure was 
repeated twice.
3.  The sample was transferred to the column with 
a pasteur pipette and the sample was then drawn 
slowly through the column. The column was 
dried under full vacuum. The procedure was 
repeated once.
4. The column was rinsed twice with 1 mL phos-
phate buffer. After each rinse it was dried under 
full vacuum.
5.  The sample was eluted four times with methanol:
TFA 99:1 (v/v) 0,25 mL. After each eluation it 
was dried under full vacuum.
6. The samples were transferred to glass vials.
Laboratory-made extraction controls
One healthy volunteer applied 2 mg cm
−2 of a 
sunscreen containing 4% BZ-3, a total of 33 g of 
sunscreen containing 1.32 g of BZ-3. All urine was 
collected for 24 hours after the application. The 
urine was diluted with urine from four healthy 
volunteers into two different concentrations, 
7.0 μmol L
−1 and 45 μmol L
−1 for BZ-3 and 0.86 
μmol L
−1 and 6.3 μmol L
−1 for DHB. 
Internal standard
BZ was used as internal standard at the concentra-
tion 5 mmol L
−1 (0.091 g). BZ was diluted in 100 
mL methanol. Volumetric ﬂ  asks, class A were used. 
The internal standard was prepared fresh every 
month and stored in a refrigerator at a temperature 
between 2 and 8 °C.
Urine collection and urine samples
25 volunteers (16 women and 9 men; mean age 
27 years, range 22–42) participated in the study. 
Height and weight were measured. Their body 
surface area (BSA) was calculated with the 
DuBois formula: BSA = 0.007184 × [height 
(cm)]0.725 × [weight (kg)]0.425). The sunscreen 
used was a commercially available sunscreen, SPF 
14 containing 4% BZ-3. Before the ﬁ  rst applica-
tion of sunscreen each volunteer gave a urine 
sample to conﬁ  rm that no BZ-3 was found in the 
urine prior to this investigation. Each volunteer 
received 2 mg cm
−2 according to his or her BSA. 
The sunscreen was distributed in plastic contain-
ers, one for each application. The amount of sun-
screen per application varied between the 
participants from 26 g to 47 g. The total amount 
of BZ-3 varied between 10.4 g to 18.8 g. BZ-3 
was measured in the urine. One volunteer was 
excluded because the written instructions were not 
followed accurately.
The volunteers were instructed to apply the 
sunscreen evenly over the entire body, with the 
exception of the scalp and genital area, morning 
and night for 5 days, a total of 10 times. They 
were allowed one shower/day before the second 
application. During the ﬁ  ve days the sunscreen 
was applied, all urine was collected, the volume 
measured and 10 mL from each sample saved and 
stored at −70 °C. Hence, each volunteer pro-
duced a different n umber of urine samples. They 
collected the urine for 5 days. After the last appli-
Table 1. Gradient program
Gradient program
Time (min) 0.1 16 18 30 31.5
Flow (ml/min) 1.0 1.0 1.9 1.9 1.04
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cation they continued to collect urine for another 
5 days, making a total of 10 days. The time of 
day, number and volume for each urine sample 
were recorded.
A total of 1234 urine samples were collected 
and analyzed.
Results
Minimum detectable limits
The minimum detectable limit was deﬁ  ned as three 
times the baseline noise level. The detection limits 
for BZ-3 and DHB were 0.01 μmol L
−1 (0.1 ng per 
0.05 mL sample) and 0.16 μmol L
−1 (2 ng per 
0.05 mL sample), respectively.
Chromatography and selectivity
Figure 2 shows chromatograms of the HPLC-
separation of BZ-3, DHB and internal standard.
It was more difﬁ  cult to achieve separation for 
DHB since there was more interference in the 
beginning of the chromatogram.
Calibration
Calibration was done against an external standard 
at ﬁ  ve different concentrations 0.04, 0.4, 4, 40 and 
100 μmol L
−1 BZ-3 and 0.03, 0.3, 3, 30, 75 μmol 
L
−1 DHB in a solution made of methanol and UF 
water.
A calibration curve was made for each sample 
series, which also consisted of extraction controls 
at low and high concentrations before each of the 
9 urine samples. Each sample series consisted of 
60 samples.
Precision and linearity
Within-day precision showed relative standard 
deviations (RSD) 10% and 11% for the low con-
centrations of BZ-3 and DHB and 7.2% and 6.6% 
for the high concentration of BZ-3 and DHB, 
respectively. Between-days precision showed RSD 
10% and 13% for the low concentrations of BZ-3 
and DHB and 8.0% and 8.7% for the high concen-
tration of BZ-3 and DHB respectively. There was 
no difference regarding precision between BZ-3 
and DHB, except for the lowest concentration of 
DHB, which exhibited greater variation (13%) 
owing to interferences in the beginning of the 
chromatogram (Fig. 2).
BZ-3, DHB and internal standard showed excel-
lent linearity with correlation coefﬁ  cient (r
2)   0.99 
for all concentrations.
Excretion pattern
BZ-3 and DHB were extensively conjugated and 
only a small proportion was excreted in the non-
conjugated form, mean values 5.9% and 8.8% 
respectively (Fig. 3).
The excretion pattern varied among the indi-
viduals. We discerned two patterns and three 
groups. Nine of the volunteers showed a pattern of 
rapid excretion of conjugated BZ-3 on the days 
when the sunscreen was being applied, followed 
by evenly decreasing excretion on the 5 consecu-
tive days when the sunscreen was not being 
applied. This is exempliﬁ  ed in Figure 4a. Seven of 
the volunteers showed a slow and even increase of 
conjugated BZ-3 during the days the sunscreen 
was being applied and a slow and even decrease 
Figure 2. Chromatograms of conjugated BZ-3, conjugated DHB and 
IS. Chromatograms from subject 8 (a) and high concentration of 
laboratory-made extraction controls (b).
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during the days the sunscreen was not applied, 
resembling a Gaussian curve. This is exempliﬁ  ed 
in Figure 4b.
Eight of the volunteers did not ﬁ  t into any of 
the patterns above (Fig. 4c), forming a third 
group.
The excretion of conjugated DHB followed 
the excretion of conjugated BZ-3 regardless of 
pattern.
Discussion
A total of 1234 samples were collected and each 
sample was analyzed for conjugated/non-conjugated 
BZ-3 and conjugated/non-conjugated DHB. More 
than 4000 samples were analyzed and we found 
this method very suitable for handling large num-
bers of samples.
Methanol/UF water was used instead of urine for 
the standard solutions because in high concentrations, 
the added BZ-3 was precipitated in the urine. For this 
reason we also included the laboratory-made extrac-
tion controls that where extracted with the SPE-
columns in the same procedure as the other urine 
samples. They were also used to control the within-
day and between-days variations, which were found 
to be sufﬁ  ciently low for the method to be considered 
stable.
As internal standard BZ was used. It is a closely 
related structural analogue of BZ-3. The use
of an internal standard provides a more correct 
quantitation.
The detection limits were at the same levels as 
in other methods, (Abdel-Nabi, Kadry et al. 1992; 
Sarveiya, Risk et al. 2004; Schakel, Kalsbeek et al. 
2004) and they were sufficient to analyze the 
samples on day 10.
Previous studies in rats have shown that BZ-3 
is extensively conjugated and excreted in the urine; 
although a small part is metabolized by cytochromes 
P-450 to DHB. DHB also undergoes extensive 
conjugation. A minor route of elimination of BZ-3 
is faeces, which were not included in the present 
study. The metabolite 2,2´-dihydroxy-4-methoxy-
benzophenone (DHMB) was not investigated since 
it was detected only in trace amounts in the urine, 
but it was the major metabolite found in faeces 
(Okereke, Kadry et al. 1993).
2,3,4-trihydroxybenzophenone (THB) is also a 
metabolite of BZ-3. However, Sarvieya et al. have 
shown that THB is only found in trace amounts in 
human urine (Sarveiya, Risk et al. 2004). In our 
experimental set-up THB had unstable properties 
and it was therefore not analyzed.
Reverse-phase HPLC is a reliable method for 
detection and quantitation. Compared to other methods 
such as gas chromatography and mass spectronomy, 
reverse-phase HPLC is in general more available, 
most laboratories have access to this method.
Many endogenous substrates are also metabo-
lized by conjugation, for example bilirubin and 
ethinylestradiol (Burchell, Brierley et al. 1995). In 
1949 the grey baby syndrome was reported, caused 
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Figure 3. The relationships between conjugated/non-conjugated BZ-3 and conjugated/non-conjugated DHB. Both BZ-3 and DHB are 
extensively conjugated in the human body.6
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by chloramphenicol toxicity in neonates due to 
their immature ability to conjugate (Sutherland, 
1959). Strasbourg et al. have shown that for chil-
dren between 13 and 24 months, the hepatic gluc-
uronidation activity was lower for a number of 
drugs (Strassburg, Strassburg et al. 2002).
Pharmacogenetics is the study of how genes 
inﬂ  uence an individual’s response to drugs. There 
are several examples of when pharmacogenetics 
is of importance. In dermatology, hydroxychloro-
quine is used to treat severe cases of polymorphic 
light eruption and discoid lupus erythematosus. 
Inherited deﬁ  ciency of glucose-6-phosphate dehy-
drogenase should be excluded before treatment 
with hydroxychloroquine is started.
There are also large inter-individual differences 
in the capacity to conjugate, for example 10% of 
the North American population is homozygous for 
the UGT1A1*28 allele. FDA has guidelines about 
the anti-cancer drug Irinotecan, stating that reduc-
tion in the starting dose should be considered for 
patients known to be homozygous for the 
UGT1A1*28 allele (FDA, 2005).
This could be one explanation why there are so 
pronounced differences in the excretion pattern 
between the subjects.
In the future the genotype might play a role in 
determining when to decide what sunscreen is best 
suited for an individual. If the person’s ability to 
conjugate is low, a sunscreen containing BZ-3 may 
not be the sunscreen of choice. There have been 
speculations about the estrogenic effects of some 
sunscreens, including BZ-3. It might not have any 
potent effect by itself but if a person is medicated 
with estrogens there might be a more potent effect 
from an endocrine active sunscreen in some indi-
viduals due to saturation of the conjugation enzymes. 
It seems that sunscreens containing BZ-3 are being 
phased out. For example, no sunscreens sold at the 
Swedish pharmacies contain BZ-3.
Future studies about genotype and sunscreens are 
needed to evaluate the importance of our ﬁ  ndings.
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